国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水

 
Guideview > Financial statements
  • BeiGene's Q1 2025 Financial report
    BeiGene's Q1 2025 Financial report Market Trend BeiGene's Q1 2025 report highlights a 50.2% revenue growth, with zanubrutinib sales exceeding 5 billion RMB and achieving its first quarterly profit under US GAAP. The company also advances its oncology pipeline globally.
  • Novo Nordisk's Q1 2025 Financial report
    Novo Nordisk's Q1 2025 Financial report Market Trend Novo Nordisk's Q1 2025 revenue surged 18% to $11.9B, driven by diabetes and obesity treatments. Wegovy sales soared 83%, while semaglutide products contributed 71% of total revenue.
  • Global Chemical Companies 2024 Financial report
    Global Chemical Companies 2024 Financial report Market Trend Quarterly and annual 2024 financial highlights from major U.S. chemical and materials companies including Dow, DuPont, Ecolab, Celanese, Linde, Air Products, and more, with detailed revenue and profit comparisons.
  • Pfizer's Q1 2025 Financial report
    Pfizer's Q1 2025 Financial report Market Trend Pfizer's Q1 2025 earnings report highlights strong adjusted EPS growth despite revenue decline. Key drivers include Comirnaty and Vyndaqel, with cost savings and R&D efficiency boosting performance.
  • Eli Lilly's Q1 2025 Financial report
    Eli Lilly's Q1 2025 Financial report Market Trend Eli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
  • AstraZeneca's Q1 2025 Financial report
    AstraZeneca's Q1 2025 Financial report Market Trend AstraZeneca's Q1 2025 revenue rose 10% to $13.59B, with strong growth in oncology and China contributing $1.8B. CEO highlights rich pipeline, U.S. expansion, and 2030 $80B revenue goal.
  • Novartis's Q1 2025 Financial report
    Novartis's Q1 2025 Financial report Market Trend Novartis reports strong Q1 2025 results with 12% sales growth, 27% core operating income increase, major FDA approvals, and raised full-year guidance amid robust innovation and strategic execution.
  • Sherwin-Williams's Q1 2025 Financial report
    Sherwin-Williams's Q1 2025 Financial report Market Trend Sherwin-Williams reported Q1 2025 revenue of $5.31B, driven by strong growth in protective and marine coatings. Despite global headwinds, the company maintained stable profits and reaffirmed full-year guidance.
  • WuXi AppTec's Q1 2025 Financial report
    WuXi AppTec's Q1 2025 Financial report Market Trend WuXi AppTec reports strong Q1 2025 results with net profit up 89% YoY and orders reaching RMB 52.33 billion. Its CRDMO model drives growth across chemistry, testing, and biology services, showing resilience amid global challenges.
  • Gilead's Q1 2025 Financial report
    Gilead's Q1 2025 Financial report Financial statements Gilead's Q1 2025 report shows stable revenue, strong HIV and hepatitis sales growth, major R&D progress, and reaffirmed full-year guidance, driven by products like Biktarvy, Trodelvy, and lenacapavir.
大荔县| 广宁县| 桃园县| 南岸区| 西昌市| 黄大仙区| 米泉市| 延寿县| 教育| 壶关县| 普兰县| 安多县| 于都县| 江西省| 永安市| 邳州市| 墨脱县| 福泉市| 崇明县| 临城县| 桃江县| 永定县| 古浪县| 汝南县| 基隆市| 华容县| 特克斯县| 大理市| 无为县| 太保市| 安图县| 商南县| 新绛县| 潞西市| 乌鲁木齐县| 桂林市| 曲阳县| 奈曼旗| 龙山县| 金阳县| 承德市|